Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

Sexually active students more likely to use STI self-testing services

Sexually transmitted infections (STIs) are at record levels in the United States, with the Centers for Disease Control and Prevention reporting recent "steep and sustained" increases.

16 Oct 2020

New trial tests combination antibody treatment for preventing COVID-19 illness

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston.

25 Sep 2020

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

25 Sep 2020

A subunit SARS-CoV-2 vaccine may offer broader protection against virus

A new study published in the preprint server bioRxiv in September 2020 reports on the structure of this protein, as revealed by cryo-electron microscopy (cryoEM).

23 Sep 2020

Study reveals damaging role of immune system in severe brain infection

A new study has detailed the damaging role played by the immune system in a severe brain condition most commonly caused by the cold sore virus.

15 Sep 2020

New discovery about STING protein could lead to improved cancer immunotherapies

The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule.

24 Aug 2020

Gene editing approach removes oral herpes

Infectious disease researchers at Fred Hutchinson Cancer Research Center have used a gene editing approach to remove latent herpes simplex virus 1, or HSV-1, also known as oral herpes.

18 Aug 2020

COVID-19 virus acts as a 'sponge' to deplete specific host microRNAs

Why is the COVID-19 virus deadly, while many other coronaviruses are fairly innocuous and just cause colds?

15 Aug 2020

New process could fast track antiviral and anticancer drug discovery

Discovering antiviral and anticancer drugs will soon be faster and cheaper thanks to new research from Simon Fraser University chemist Robert Britton and his international team.

7 Aug 2020

Penis microbiome is reservoir for bacterial vaginosis-associated bacteria

Previous studies have pointed out that the reproductive microbiomes of partners might be exchanged in bacterial vaginosis (BV). Now, a team of researchers at the University of Illinois in Chicago compared the microbiota of couples before and after the development of BV.

4 Aug 2020

Combination of certain drugs can do more harm than good, shows study

A team of researchers at the Norwegian University of Science and Technology (NTNU) investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.

29 Jul 2020

Researchers discover new method to treat herpes viruses

Researchers at Lund University in Sweden have discovered a new method to treat human herpes viruses. The new broad-spectrum method targets physical properties in the genome of the virus rather than viral proteins, which have previously been targeted.

24 Jul 2020

Cerebrospinal fluid autoantibodies target the brain in some COVID-19 patients

A study conducted by German researchers has shown that the neurological symptoms observed in some patients with coronavirus disease 2019 (COVID-19) may be caused by autoantibodies targeting the brain.

7 Jul 2020

Antidepressant fluoxetine (Prozac) suppresses replication of SARS-CoV-2

A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.

16 Jun 2020

Maternal SARS-CoV-2 infection not harmful in first trimester pregnancies

A new Danish study published on the preprint server medRxiv in June 2020 shows that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in early pregnancy does not carry an increased risk of fetal harm.

10 Jun 2020

Study shows safety of new cell therapy approaches for kidney transplant recipients

A large international study coordinated by University Hospital Regensburg and Charité - Universitätsmedizin Berlin has demonstrated the safety of new cell therapy approaches for use in kidney transplant recipients.

10 Jun 2020

Specific immune suppression leads to severe COVID-19 disease

A new study published online on the preprint server medRxiv in May 2020 reports that specific changes in the way the human immune system responds to COVID-19 determine whether the individual develops moderate or severe illness.

2 Jun 2020

Heparin may stop SARS-CoV-2 infecting host cells

Researchers at the University of Sheffield have developed a new assay that can be used to assess the attachment of viruses to host cells and to test potential inhibitors of viral infection.

24 May 2020

Researchers discover molecular mechanism that helps HSV1 infect the brain

Herpes simplex virus (HSV1) infections are initiated at mucosal surfaces where the virus infects epithelial cells.

8 May 2020

Study reveals antiviral properties of glycosaminoglycans against SARS-CoV-2

Glycosaminoglycans can inhibit cell invasion by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other coronaviruses, which supports the utilization of such therapeutics in the fight against coronavirus disease (COVID-19) – reports a new study available on the preprint server bioRxiv.

3 May 2020